1st SOHO Asia to be held in January 2026

SOHO Asia 2026 will focus on the latest advances in leukemia, lymphoma, multiple myeloma, and myeloproliferative neoplasms (MPNs), featuring leading.

by SOHO Insider Editors
December 5, 2025

Phase 1 study of menin inhibitor terminated early due to lack of response, differentiation syndrome

Kerri Fitzgerald December 3, 2025

A first-in-human study of the menin inhibitor DS-1594b in patients with acute leukemias was discontinued early due to lack of efficacy as a monotherapy and the occurrence of differentiation syndrome (DS) in nearly a third of patients.

Read More ➔

Extramedullary disease in MM associated with severe toxicities following BCMA-targeted CAR T-cell therapy

Leah Sherwood December 2, 2025

Extramedullary disease (EMD) in multiple myeloma (MM) is associated with significantly higher rates of severe toxicity following B-cell maturation antigen (BCMA)-targeted CAR T-cell therapy, according to a new paper published in Haematologica.

Read More ➔

Drs. Jabbour, Logan, and Aldoss discuss treatment advancements in ALL

SOHO Insider Editors December 1, 2025

In this panel discussion at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Elias Jabbour, MD, leukemia professor at the University of Texas MD Anderson Cancer Center, moderates a discussion on acute lymphoblastic leukemia (ALL) treatment with Aaron Logan, MD, PhD, from the University of California, San Francisco, and Ibrahim T. Aldoss, MD, from the City of Hope.

Read More ➔

Dr. Sundar Jagannath defines ‘cure’ in multiple myeloma

SOHO Insider Editors November 30, 2025

In this interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Sundar Jagannath, MD, professor of medicine at the Icahn School of Medicine at Mount Sinai in New York discusses what cure means in multiple myeloma and why there is an urgent need for a formal definition for it in the field.

Read More ➔

FDA adds enterocolitis risk warning to approved CAR-T cell therapy

SOHO Insider Editors November 28, 2025

The US Food and Drug Administration (FDA) approved updates to the prescribing information for ciltacabtagene autoleucel (CARVYKTI). The agency added a boxed warning for immune effector cell-associated enterocolitis (IEC-EC).

Read More ➔